This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
NewLink Genetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked biomedical stocks worth considering are Alexion Pharmaceuticals, Inc. (ALXN), Biogen Idec Inc. (BIIB) and Actelion Ltd. (ALIOF). While Alexion and Biogen sport a Zacks Rank #1 (Strong Buy), Actelion carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment